Dimethyl fumarate for multiple sclerosis

Papadopoulou, Athina and D'Souza, Marcus and Kappos, Ludwig and Yaldizli, Ozgür. (2010) Dimethyl fumarate for multiple sclerosis. Expert opinion on investigational drugs, Vol. 19, no. 12. pp. 1603-1612.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003843

Downloads: Statistics Overview


One of the disadvantages of currently available disease-modifying drugs (DMDs) for multiple sclerosis (MS) is their parenteral administration. Moreover, efficacy is only partial. Most patients treated with first-line DMDs do not remain relapse-free. There is a need for new oral drugs that are more effective than currently available compounds. Innovative oral drugs with new mechanisms of action showed promising results in clinical trials. One of these emerging drugs is BG00012 (BG-12), a fumaric acid ester (FAE). Its active agent, dimethyl fumarate had first been included in FAE treatments for psoriasis.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Informa Healthcare
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:24 May 2013 09:12
Deposited On:26 Apr 2013 06:54

Repository Staff Only: item control page